Edwin O Were1, Renee Heffron, Nelly R Mugo, Connie Celum, Andrew Mujugira, Elizabeth A Bukusi, Jared M Baeten. 1. aDepartment of Reproductive Health, Moi University, Eldoret, Kenya bDepartment of Global Health, University of Washington, Seattle, Washington, USA cCentre for Clinical Research dCentre for Microbiology Research, Kenya Medical Research Institute eDepartment of Obstetrics and Gynecology, Kenyatta National Hospital, Nairobi, Kenya fDepartment of Medicine gDepartment of Epidemiology hDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA. *Members of the Partners PrEP Study Team are listed in the Acknowledgements section.
Abstract
BACKGROUND: There is a paucity of data on the effect of antiretroviral medications on male fertility. Couples affected by HIV-1 often have fertility intentions, and antiretroviral medications, as both treatment of HIV-1-infected persons and pre-exposure prophylaxis (PrEP) for uninfected persons, are part of peri-conception risk reduction. METHODS: Within a randomized, placebo-controlled trial of daily oral tenofovir disoproxil fumarate (TDF) and combination emtricitabine (FTC)/TDF PrEP for HIV-1 prevention conducted among heterosexual HIV-1-serodiscordant couples, we assessed the impact of TDF and FTC/TDF use on male fertility, measured as incident pregnancy in female partners of men assigned toPrEP vs. placebo. RESULTS: Of the 2962 HIV-1-uninfected men partners, 986 were randomized to TDF, 1013 to FTC/TDF, and 963 toplacebo. The overall pregnancy incidence in their HIV-1-infected female partners was 12.9 per 100 person-years and did not differ significantly across the study arms (13.2 TDF, 12.4 FTC/TDF, 13.2 placebo). The frequency of live births, pregnancy losses, and gestational age at birth or loss was also statistically similar in the three randomization groups. CONCLUSION:TDF and FTC/TDF, when used as PrEP by HIV-1-uninfected men, did not adversely affect male fertility or pregnancy outcomes.
RCT Entities:
BACKGROUND: There is a paucity of data on the effect of antiretroviral medications on male fertility. Couples affected by HIV-1 often have fertility intentions, and antiretroviral medications, as both treatment of HIV-1-infectedpersons and pre-exposure prophylaxis (PrEP) for uninfected persons, are part of peri-conception risk reduction. METHODS: Within a randomized, placebo-controlled trial of daily oral tenofovir disoproxil fumarate (TDF) and combination emtricitabine (FTC)/TDF PrEP for HIV-1 prevention conducted among heterosexual HIV-1-serodiscordant couples, we assessed the impact of TDF and FTC/TDF use on male fertility, measured as incident pregnancy in female partners of men assigned to PrEP vs. placebo. RESULTS: Of the 2962 HIV-1-uninfectedmen partners, 986 were randomized to TDF, 1013 to FTC/TDF, and 963 to placebo. The overall pregnancy incidence in their HIV-1-infected female partners was 12.9 per 100 person-years and did not differ significantly across the study arms (13.2 TDF, 12.4 FTC/TDF, 13.2 placebo). The frequency of live births, pregnancy losses, and gestational age at birth or loss was also statistically similar in the three randomization groups. CONCLUSION:TDF and FTC/TDF, when used as PrEP by HIV-1-uninfectedmen, did not adversely affect male fertility or pregnancy outcomes.
Authors: R Slama; F Eustache; B Ducot; T K Jensen; N Jørgensen; A Horte; S Irvine; J Suominen; A G Andersen; J Auger; M Vierula; J Toppari; A N Andersen; N Keiding; N E Skakkebaek; A Spira; P Jouannet Journal: Hum Reprod Date: 2002-02 Impact factor: 6.918
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Kristine B Patterson; Heather A Prince; Eric Kraft; Amanda J Jenkins; Nicholas J Shaheen; James F Rooney; Myron S Cohen; Angela D M Kashuba Journal: Sci Transl Med Date: 2011-12-07 Impact factor: 17.956
Authors: Elisabeth van Leeuwen; Ferdinand W Wit; Sjoerd Repping; Jan Karel M Eeftinck Schattenkerk; Peter Reiss; Fulco van der Veen; Jan M Prins Journal: AIDS Date: 2008-03-12 Impact factor: 4.177
Authors: Frank Taulo; Mark Berry; Amy Tsui; Bonus Makanani; George Kafulafula; Qing Li; Chiwawa Nkhoma; Johnstone J Kumwenda; Newton Kumwenda; Taha E Taha Journal: AIDS Behav Date: 2009-03-24
Authors: Andrew Mujugira; Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; Linda Barnes; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Lara Kidoguchi; Dana Panteleeff; Meighan Krows; Heena Shah; Jennifer Revall; Susan Morrison; Lisa Ondrejcek; Charlotte Ingram; Robert W Coombs; Jairam R Lingappa; Connie Celum Journal: PLoS One Date: 2011-10-05 Impact factor: 3.240
Authors: D Joseph Davey; S West; V Umutoni; S Taleghani; H Klausner; E Farley; R Shah; S Madni; S Orewa; V Kottamasu; V Rice; Z Robbin; K M Wall Journal: AIDS Behav Date: 2018-09
Authors: Sigcinile Dlamini; Michael Kuipa; Kim Enfield; Salndave Skosana; John G Woodland; Johnson Mosoko Moliki; Alexis J Bick; Zephne van der Spuy; Michelle F Maritz; Chanel Avenant; Janet P Hapgood Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Lynn T Matthews; Jolly Beyeza-Kashesya; Ian Cooke; Natasha Davies; Renee Heffron; Angela Kaida; John Kinuthia; Okeoma Mmeje; Augusto E Semprini; Shannon Weber Journal: AIDS Behav Date: 2018-06